在肺动脉高血压中参与血管改造的生长因子
1Department of Physiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.
Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi
|September 3, 2025
概括
通过促进肺动脉光滑肌细胞的增殖,血小板衍生生长因子 (PDGF) 驱动肺动脉高血压 (PAH). 用伊马替尼或冠状酸抑制PDGF信号,减少了细胞生长,改善了大鼠的血管重塑.
科学领域:
- 心血管研究
- 肺高血压的病理理学
- 分子生物学
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的心血管疾病,其特征是肺血管重塑和肺动脉压升高 (PAP).
- 这种重塑涉及肺动脉光滑肌细胞 (PASMCs) 的过度增殖和迁移,这一过程受到与受体氨酸激酶结合的生长因子的影响.
- 之前的研究发现PASMC中的Ca2+感应受体升高是PAH发展的一个因素,与PDGF水平升高有关.
研究的目的:
- 审查生长因子,特别是血小板衍生生长因子 (PDGF) 在肺动脉高血压 (PAH) 的发病和进展中的病理作用.
- 突出PDGF诱导的PASMC增殖和迁移对PAH肺血管重塑的作用.
主要方法:
- 对PAH相关生长因子的现有文献的审查.
- 分析PDGF及其信号通路在PASMC扩散和迁移中的作用.
- 检查PDGF抑制剂 (imatinib,酸) 对PASMC和肺高血压动物模型的影响.
主要成果:
- 在PAH患者中增加的PDGF水平可提高PASMC中Ca2+感应受体的调节,从而导致PAH.
- 通过抑制PDGF信号,伊马替尼和冠状酸抑制了PASMC的过度扩散和迁移.
- 在小鼠肺高血压模型中,这些疗法在改善肺血管重塑方面表现出有效性.
结论:
- 血小板衍生生长因子 (PDGF) 在肺动脉高血压 (PAH) 的发病和进展中起着关键作用.
- 通过制PASMC扩散和肺血管重塑,针对PDGF信号通路提供了PAH的潜在治疗策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Pulmonary Hypertension: Classification and Pathogenesis
284
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
284
Role of Hematopoietic Growth Factors
1.7K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Mechanism of Angiogenesis
5.8K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K


